Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690880 · ClinicalTrials.gov registry record
ForeseeHome NRich Registry
A clinical trial of Age-related Macular Degeneration, sponsored by Notal Vision.
- Active
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT05690880 is a study of Age-related Macular Degeneration that is active but no longer recruiting, run by Notal Vision. The registered enrollment target is 20,000 participants, above the 1,237-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (1517% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05690880, a study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Notal Vision.
- ACTIVE NOT RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during routine care with Spectral Domain Optical Coherence Tomography (SD-OCT) and to validate the predictive value of a non-NV-AMD FSH alerts.
Conditions Studied
Interventions
- DEVICE Foresee Home
Study Locations (1)
New Jersey
- NJ Retina - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2027-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05690880
The ClinicalTrials.gov registry entry for NCT05690880 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,237-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (1517% higher). The listed sponsor is Notal Vision, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Foresee Home is the first listed.
NCT05690880 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05690880 about?
NCT05690880 is a clinical study titled "ForeseeHome NRich Registry". This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during routine care with Spectral Domain Optical Coherence Tomography (SD-OCT) and t...
What is the current status of trial NCT05690880?
This trial is currently active not recruiting. The enrollment target is 20,000 participants. The study started on 2022-12-15. Estimated completion is 2027-12-15.
What conditions does trial NCT05690880 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05690880?
The interventions under investigation include: Foresee Home (DEVICE).
Who is sponsoring clinical trial NCT05690880?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05690880 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.